WVP
LRMR icon

Worth Venture Partners’s Larimar Therapeutics LRMR Stock Holding History

Worth Venture Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-59,468
Closed -$550K – 128
2020
Q1 		$550K Buy
59,468
+14,270
+32% +$188K 0.34% 43
2019
Q4 		$602K Buy
45,198
+6,994
+18% +$66.8K 0.29% 43
2019
Q3 		$338K Buy
38,204
+16,075
+73% +$176K 0.19% 57
2019
Q2 		$316K Buy
+22,129
New +$589K 0.18% 56

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Worth Venture Partners's LRMR Position: Q2 2020 in Review

Worth Venture Partners sold out of Larimar Therapeutics (LRMR) in Q2 2020, closing a stake of 59,468 shares — an estimated $550K sold.

Worth Venture Partners first reported a position in LRMR in Q2 2019 and held it in 4 quarters. The position peaked at $602K in Q4 2019. 37 funds tracked by Wall St. Rank hold LRMR as of Q2 2020.

  • Worth Venture Partners reported no remaining Larimar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Worth Venture Partners sold 59,468 Larimar Therapeutics shares in Q2 2020, an estimated $550K.
  • Worth Venture Partners first reported a position in Larimar Therapeutics in Q2 2019 and held it in 4 quarters.
  • Worth Venture Partners's Larimar Therapeutics position peaked at $602K in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2020.

Based on Worth Venture Partners's 13F filing for Q2 2020, filed 14 Aug 2020.